Trial Profile
Resistant mechanisms to afatinib in non-small cell lung cancer with EGFR mutations
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Oct 2016 New trial record